No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
473681 |
1. Apply sex-specific ruleNone |
473681 |
2. Check conditionsNone |
473681 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
21636 |
4. Check minimum number of events
Min. number of events
3
|
21636 |
5. Include endpointsNone |
21636 |
6. Filter based on genotype QC (FinnGen only) |
21027 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
First used in FinnGen datafreeze
DF5
Similar endpoints
↥List of similar endpoints to
Glucosamine medication
based on the number of shared cases.
Similar with more cases:
- Oter anti-inflammatory and antirheumatic agents, non-steroids
- Anti-inflammatory and antirheumatic products, non-steroids
- Paracetamol of NSAID medication
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 170709 | 124457 | 45987 |
| Only index persons | 165597 | 121384 | 44213 |
| Unadjusted period prevalence (%) | |||
| Whole population | 2.95 | 3.56 | 1.28 |
| Only index persons | 3.72 | 4.46 | 1.69 |
| Median age at first event (years) | |||
| Whole population | 63.99 | 64.49 | 62.57 |
| Only index persons | 63.62 | 64.15 | 62.17 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 21027 | 14721 | 6306 |
| Unadjusted period prevalence (%) | 5.00 | 5.78 | 3.17 |
| Median age at first event (years) | 60.18 | 59.66 | 61.40 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
Mortality – FinRegistry
↥Association
Association between endpoint RX_GLUCOSAMINE and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| RX_GLUCOSAMINE | 0.713 [0.67, 0.76] | < 0.001 |
| Birth year | 0.995 [0.99, 1.0] | 0.177 |
During the follow-up period (1.1.1998 — 31.12.2019), 28852 out of 124457 females with RX_GLUCOSAMINE died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| RX_GLUCOSAMINE | 0.752 [0.7, 0.81] | < 0.001 |
| Birth year | 0.985 [0.98, 0.99] | 0.001 |
During the follow-up period (1.1.1998 — 31.12.2019), 12733 out of 45987 males with RX_GLUCOSAMINE died.
Mortality risk
Mortality risk for people of age
years, who have RX_GLUCOSAMINE.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.076% | 0.165% |
| 5 | 0.375% | 0.87% |
| 10 | 0.941% | 2.159% |
| 15 | 1.94% | 3.96% |
| 20 | 3.469% | 6.678% |
Relationships between endpoints
↥Index endpoint: RX_GLUCOSAMINE – Glucosamine medication
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
Extremity
rg [CI]
Extremity
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data